Fung, famotidine prophylaxis study: no change in mortality [p=1], 6% lower hospitalization [p=0.0002], and 12% more cases [p<0.0001] https://c19p.org/fungfm
copied to clipboard
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (date from earlier preprint)
Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
|
risk of death, no change, HR 1.00, p = 1.00, vs. never used.
|
|
risk of hospitalization, 6.0% lower, HR 0.94, p < 0.001, vs. never used.
|
|
risk of case, 12.0% higher, HR 1.12, p < 0.001, vs. never used.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients.
Fung et al., 1 Oct 2021, retrospective, population-based cohort, USA, peer-reviewed, 6 authors.
fung
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.